Laxel Medical

Laxxon Medical is a private pharma-technology company developing advanced drug delivery systems using its proprietary SPID® 3D screen-printing platform. The company focuses on oral dosage forms that can tailor release profiles, improve bioavailability, and enable multi-compartment formulations for complex active ingredients, including peptides and small molecules. Its disclosed in-house pipeline includes LXM.2, an oral GLP-1 receptor agonist program for obesity/weight loss, and LXM.5, a levodopa/carbidopa program for Parkinson's disease. Laxxon also works with external pharmaceutical partners on formulation development and manufacturing, including cGMP production through its CDMO collaboration with Adare. The business appears to be positioned as both a platform company and a product developer centered on next-generation oral drug delivery.